Real-world experience of emicizumab prophylaxis in Korean children with severe hemophilia A without inhibitors
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Real-world experience of emicizumab prophylaxis in Korean children with severe hemophilia A without inhibitors ; volume:59 ; number:1 ; day:18 ; month:10 ; year:2024 ; pages:1-6 ; date:12.2024
Blood research ; 59, Heft 1 (18.10.2024), 1-6, 12.2024
- Urheber
-
Kim, Sung Eun
Kim, Ji Yoon
Park, Jeong A.
Lyu, Chuhl Joo
Hahn, Seung Min
Han, Jung Woo
Park, Young Shil
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s44313-024-00039-1
- URN
-
urn:nbn:de:101:1-2501072124147.125188141058
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:32 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Kim, Sung Eun
- Kim, Ji Yoon
- Park, Jeong A.
- Lyu, Chuhl Joo
- Hahn, Seung Min
- Han, Jung Woo
- Park, Young Shil
- SpringerLink (Online service)
Ähnliche Objekte (12)
Cerebellar hematoma in severe hemophilia with inhibitor on emicizumab prophylaxis: a case report
Cost-Effectiveness Analysis of Pharmacokinetic-Guided Prophylaxis Versus Standard Prophylaxis in Adults with Severe Hemophilia A in China
Pharmacokinetic model-based assessment of factor IX prophylaxis treatment regimens in severe hemophilia B
Femoral Fractures in Severe Hemophilia
Expert Opinion for Defining a Severe Bleeding Phenotype to Guide Prophylaxis in Patients with Nonsevere Hemophilia
Letter to the Editor Regarding “Cost-Effectiveness Analysis of Pharmacokinetic-Guided Prophylaxis Versus Standard Prophylaxis in Adults with Severe Hemophilia A in China”
Adherence and Cost Effectivity of Home-Based Prophylaxis Over Institutionalized Prophylaxis in Patients with Hemophilia
Nonacog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Patients with Moderately Severe or Severe Hemophilia B in India
A Response to: Letter to the Editor Regarding “Cost-Effectiveness Analysis of Pharmacokinetic-Guided Prophylaxis Versus Standard Prophylaxis in Adults with Severe Hemophilia A in China”
Prophylaxis in older Canadian adults with hemophilia A: lessons and more questions
Modeling to Predict Factor VIII Levels Associated with Zero Bleeds in Patients with Severe Hemophilia A Initiated on Tertiary Prophylaxis
Treatment patterns and bleeding outcomes in persons with severe hemophilia A and B in a real-world setting
Cerebellar hematoma in severe hemophilia with inhibitor on emicizumab prophylaxis: a case report
Cost-Effectiveness Analysis of Pharmacokinetic-Guided Prophylaxis Versus Standard Prophylaxis in Adults with Severe Hemophilia A in China
Pharmacokinetic model-based assessment of factor IX prophylaxis treatment regimens in severe hemophilia B
Femoral Fractures in Severe Hemophilia
Expert Opinion for Defining a Severe Bleeding Phenotype to Guide Prophylaxis in Patients with Nonsevere Hemophilia
Letter to the Editor Regarding “Cost-Effectiveness Analysis of Pharmacokinetic-Guided Prophylaxis Versus Standard Prophylaxis in Adults with Severe Hemophilia A in China”
Adherence and Cost Effectivity of Home-Based Prophylaxis Over Institutionalized Prophylaxis in Patients with Hemophilia
Nonacog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Patients with Moderately Severe or Severe Hemophilia B in India
A Response to: Letter to the Editor Regarding “Cost-Effectiveness Analysis of Pharmacokinetic-Guided Prophylaxis Versus Standard Prophylaxis in Adults with Severe Hemophilia A in China”
Prophylaxis in older Canadian adults with hemophilia A: lessons and more questions
Modeling to Predict Factor VIII Levels Associated with Zero Bleeds in Patients with Severe Hemophilia A Initiated on Tertiary Prophylaxis
Treatment patterns and bleeding outcomes in persons with severe hemophilia A and B in a real-world setting
Cerebellar hematoma in severe hemophilia with inhibitor on emicizumab prophylaxis: a case report
Cost-Effectiveness Analysis of Pharmacokinetic-Guided Prophylaxis Versus Standard Prophylaxis in Adults with Severe Hemophilia A in China
Pharmacokinetic model-based assessment of factor IX prophylaxis treatment regimens in severe hemophilia B
Femoral Fractures in Severe Hemophilia
Expert Opinion for Defining a Severe Bleeding Phenotype to Guide Prophylaxis in Patients with Nonsevere Hemophilia
Letter to the Editor Regarding “Cost-Effectiveness Analysis of Pharmacokinetic-Guided Prophylaxis Versus Standard Prophylaxis in Adults with Severe Hemophilia A in China”
Adherence and Cost Effectivity of Home-Based Prophylaxis Over Institutionalized Prophylaxis in Patients with Hemophilia
Nonacog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Patients with Moderately Severe or Severe Hemophilia B in India
A Response to: Letter to the Editor Regarding “Cost-Effectiveness Analysis of Pharmacokinetic-Guided Prophylaxis Versus Standard Prophylaxis in Adults with Severe Hemophilia A in China”
Prophylaxis in older Canadian adults with hemophilia A: lessons and more questions
Modeling to Predict Factor VIII Levels Associated with Zero Bleeds in Patients with Severe Hemophilia A Initiated on Tertiary Prophylaxis